GlassScriptPhysician profile
Jacob Barish
NPI 1154853414
$9,750.70
in general payments reported to CMS, 2019-2025
59 companies · $5,799 in 2025
The $5,799 reported for 2025 was more than what 75% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $117 · 2024: $3,835 · 2025: $5,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,764 · Long Term Medical Supply Or Device Loan: $798 · Education: $71.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,764.27 |
| Long Term Medical Supply Or Device Loan | $797.60 |
| Education | $71.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,362.87 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $898.58 | 2024-2025 | Enhertu, Imfinzi, Lynparza |
| Pfizer INC. | $651.43 | 2024-2025 | |
| Janssen Biotech, INC. | $604.41 | 2024-2025 | Erleada, Akeega, Rybrevant |
| Merck Sharp & Dohme LLC | $579.11 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Eisai INC. | $406.22 | 2024-2025 | |
| Abbvie INC. | $365.94 | 2024-2025 | |
| Celgene Corporation | $311.52 | 2024-2025 | Reblozyl, Pomalyst, Opdivo |
| Gilead Sciences, INC. | $288.49 | 2024-2025 | Trodelvy |
| Incyte Corporation | $287.31 | 2024-2025 | Jakafi, Zynyz, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $233.31 | 2024-2025 | |
| Sobi, INC | $209.78 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $196.94 | 2022-2025 | Opdivo, Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $184.96 | 2024-2025 | Fruzaqla, Ninlaro |
| Array Biopharma INC | $165.51 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $156.74 | 2024-2025 | |
| Geron Corporation | $150.19 | 2025 | Rytelo |
| Baxter Healthcare | $149.98 | 2024 | Tisseel |
| Glaxosmithkline, LLC. | $144.41 | 2024-2025 | Ojjaara, Blenrep |
| Kite Pharma, INC. | $130.42 | 2024-2025 | Yescarta |
| Alexion Pharmaceuticals, INC. | $129.97 | 2024-2025 | Ultomiris |
| Astellas Pharma US INC | $128.05 | 2024-2025 | Vyloy, Xtandi |
| Servier Pharmaceuticals LLC | $118.80 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $115.16 | 2024-2025 | Libtayo |
| Blueprint Medicines Corporation | $111.51 | 2024-2025 | Ayvakit |
| Pharmacosmos Therapeutics INC. | $100.44 | 2024-2025 | Monoferric, Cosela |
| Genmab U.S., INC. | $86.57 | 2024-2025 | Epkinly |
| Daiichi Sankyo INC. | $81.64 | 2024-2025 | Datroway, Vanflyta |
| Mirati Therapeutics, INC. | $81.07 | 2024 | Krazati |
| Pharmaessentia USA Corporation | $78.91 | 2024-2025 | Besremi |
| Emd Serono, INC. | $78.78 | 2024-2025 | |
| Genentech USA, INC. | $78.78 | 2024-2025 | Polivy, Tecentriq, Venclexta |
| Adc Therapeutics America, INC. | $77.42 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $76.62 | 2024-2025 | Provenge |
| Jazz Pharmaceuticals INC. | $67.73 | 2024-2025 | |
| Tersera Therapeutics LLC | $65.53 | 2025 | Zoladex |
| Beone Medicines USA, INC. | $62.30 | 2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $53.89 | 2024-2025 | Xpovio |
| Ipsen Biopharmaceuticals, INC | $53.72 | 2024 | Onivyde, Somatuline Depot |
| Taiho Oncology, INC. | $51.63 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $47.46 | 2024-2025 | Pyrukynd |
| Novocure INC. | $44.43 | 2025 | Optune Lua (Novottf-200t) |
| Fennec Pharmaceuticals, INC. | $44.02 | 2024-2025 | Pedmark, Fyarro |
| Myriad Genetic Laboratories, INC. | $39.93 | 2024 | Myrisk |
| Beigene USA, INC. | $37.72 | 2024-2025 | Brukinsa |
| Puma Biotechnology, INC. | $37.39 | 2024-2025 | |
| Lilly USA, LLC | $32.78 | 2025 | Verzenio, Jaypirca |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.04 | 2025 | |
| Exelixis INC. | $30.44 | 2025 | Cabometyx |
| Deciphera Pharmaceuticals INC. | $28.49 | 2025 | Qinlock, Romvimza |
| Sumitomo Pharma America, INC. | $28.49 | 2024 | Orgovyx |
| Legend Biotech USA INC. | $26.46 | 2025 | Carvykti |
| Pharmaand Gmbh | $26.29 | 2025 | Rubraca |
| Tolmar, INC. | $26.29 | 2025 | Rubraca, Eligard |
| Nuvation Bio INC. | $25.02 | 2025 | Ibtrozi |
| Recordati_rare_diseases_inc. | $22.50 | 2025 | Enjaymo |
| Stemline Therapeutics INC. | $19.11 | 2025 | Orserdu |
| Alnylam Pharmaceuticals INC. | $14.12 | 2024 | Givlaari |
| Veracyte, INC. | $11.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Barish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.